Multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of etripamil nasal spray for the resolution of spontaneous episodes of paroxysmal supraventricular tachycardia. RAPID Study (NODE-301 Part 2)
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: MILESTONE PHARMACEUTICALS, INC.
- Phase: III
- Execution start: 15/04/2021
- End of execution: 31/12/2021
- IP: LUIS TERCEDOR SANCHEZ